Amgen Inc. (AMGN) research, news, and more from GeoInvesting

Company description

Wed, 05 Mar 2008 05:00:00 GMT

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Comments & Business Outlook

Mon, 27 Jul 2009 04:00:00 GMT

Revenues for 2009 are trending towards the upper end of the current guidance range of $14.4 to $14.8 billion. Amgen has increased its previously issued earrings per share guidance range and now expects 2009 adjusted EPS to be in the range of $4.80 to $4.95, an increase from the previous range of $4.55 to $4.75.

FULL YEAR 2009 Guidance Ending December ^a

	Full Year 2009 Guidance	Full Year 2008 Reported	Period Change
GAAP Revenue	$14.4 to $14.8 billion	$15.0 billion	-4.0% to -1.3%
Non-GAAP EPS ^b	$4.80 to $4.95	$4.55	5.5% to 8.8%

Source: See Release, July 27, 2009

^a The above forecasts reflect the Company's current and preliminary views and are therefore subject to change. Please refer to the Company's Safe Harbor Statement (usually in press releases) for the factors that could cause actual results to differ materially from those contained in any forward-looking statement.

^b Non-GAAP EPS figures generally exclude certain non-operating gains and losses as well as certain non-cash items. Non-GAAP information should not be viewed in isolation or as a substitute for reported, or GAAP information . For a more complete explanation of the company's definition of non-GAAP please refer to its financial press releases. The GeoTeam® non-GAAP figures may, from time to time, differ from company supplied figures.

Comments & Business Outlook

Mon, 26 Jan 2009 05:00:00 GMT

Guidance Report:

2009 Revenue Guidance	2009 EPS Guidance	*2008 Reported EPS	*Implied EPS Growth Rate
$14.8 to $15.2 billion	$4.55 to $4.75	$4.55	0 to 4.3%

* EPS Figures exclude one time charges and gains (Non-GAAP).

Source: PR Newswire (January 26, 2009)